Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.34 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 6/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358192 | 1.00 | CYP2B6 (0.34) | CYP2B6TENT4ATENT4BRENDRD2 | |
| SCHEMBL25832385 | 0.91 | TLR8 (0.33) | — | |
| SCHEMBL21358515 | 0.85 | CYP2B6 (0.39) | CYP2B6TENT4ATENT4BREN | |
| SCHEMBL21358516 | 0.85 | CYP2B6 (0.39) | CYP2B6TENT4ATENT4BREN | |
| SCHEMBL30893764 | 0.84 | CYP2B6 (0.37) | CYP2B6TENT4ATENT4B | |
| SCHEMBL30893763 | 0.79 | CYP2B6 (0.38) | CYP2B6TENT4ATENT4B | |
| SCHEMBL27200101 | 0.79 | CYP2B6 (0.38) | CYP2B6TENT4ATENT4B | |
| SCHEMBL25832354 | 0.76 | EHMT2 (0.32) | CYP2B6TENT4ATENT4BDRD2DRD4 | |
| SCHEMBL21358513 | 0.76 | CYP2B6 (0.37) | CYP2B6TENT4ATENT4BREN | |
| SCHEMBL21358511 | 0.76 | CYP2B6 (0.37) | CYP2B6TENT4ATENT4BREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-01-21 | — | — | US | disclosed |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-01-21 | — | — | US | disclosed |
| WO-2019177937-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | CYP2B6 19/4885TENT4A 921/4885TENT4B 1050/4885 |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HPD, CYP24A1 | CYP2B6 19/4885TENT4A 921/4885TENT4B 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.